A lack of disease-modifying treatment strategies for Alzheimer's disease (AD) results in part from an incomplete understanding of the earliest molecular changes, when there is opportunity for reversal. A body of evidence shows that synaptic dysfunction precedes amyloid-beta (AB) deposition, suggesting that the synaptic compartment is a key site of early pathology. Accurate localization of events to terminals is difficult;therefore, our laboratory has developed methods for flow cytometry analysis of synaptosomes prepared from cryopreserved human and rodent tissue. This technique allows 1) study of populations of individual terminals (5-10,000 particles/sample) and 2) absolute quantification of synaptic AB, phosphorylated tau (p-tau), and lipid and synaptic markers in postmortem human cases and in transgenic disease models. Flow cytometry results will be verified by biochemical assays and confocal and electron microscopy. Our first studies of postmortem AD synaptic terminals showed that ~50% of terminals in AD association cortex are strongly AB-positive. Subsequent experiments have shown that similar AB accumulations occur in the Tg2576 mouse model of AD, and that the AB buildup is accompanied by a significant increase in free cholesterol and GM1 ganglioside. Our general working hypothesis is that synaptic terminal AB accumulation is a key intermediate in synaptic dysfunction prior to loss, and a potential sources or seed for AB deposition in plaques. The specific hypothesis for this project is that cholesterol in lipid raft domains enhances processing of APP to AB;therefore manipulation of terminal cholesterol via ApoE genotype and drug treatment will alter the accumulation of AB and related lipids and peptides, and will affect synaptic function. In the first Specific Aim, our goal is to determine the relationship of synaptic terminal AB to regional AD pathology, disease stage, and apoE isotype in human samples and transgenic mouse models. In the second Specific Aim, we will use dual transgenic mice to determine the effect of apoE isotype on terminals levels of AB, cholesterol and related lipids, and on synaptic function. In addition, we will study the effect of hydrophobic vs. hydrophilic statins on terminal AB accumulation. The third Specific Aim has the goal of identifying the AB peptide species in terminals along with associated changes in signaling pathways, particularly integrin focal adhesion complexes and downstream deregulation of kinase/phosphatase activity. Development of therapeutic strategies for Alzheimer's disease requires a complete understanding of the earliest pathological changes when there is still opportunity for reversal. The present project has the long term goal of identifying potential drug targets and examines pathologic changes in synaptic terminals from Alzheimer's cases and mouse models that are treated with cholesterol lowering drugs. These experiments will help us to understand how cholesterol may contribute to Alzheimer's pathology.

National Institute of Health (NIH)
National Institute on Aging (NIA)
Research Project (R01)
Project #
Application #
Study Section
Cell Death in Neurodegeneration Study Section (CDIN)
Program Officer
Petanceska, Suzana
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of California Los Angeles
Schools of Nursing
Los Angeles
United States
Zip Code
Gonzalez, Bianca; Abud, Edsel M; Abud, Abigail M et al. (2017) Tau Spread, Apolipoprotein E, Inflammation, and More: Rapidly Evolving Basic Science in Alzheimer Disease. Neurol Clin 35:175-190
Bilousova, Tina; Miller, Carol A; Poon, Wayne W et al. (2016) Synaptic Amyloid-? Oligomers Precede p-Tau and Differentiate High Pathology Control Cases. Am J Pathol 186:185-98
Wang, David B; Kinoshita, Yoshito; Kinoshita, Chizuru et al. (2015) Loss of endophilin-B1 exacerbates Alzheimer's disease pathology. Brain 138:2005-19
Sokolow, Sophie; Henkins, Kristen M; Bilousova, Tina et al. (2015) Pre-synaptic C-terminal truncated tau is released from cortical synapses in Alzheimer's disease. J Neurochem 133:368-79
Tai, Leon M; Bilousova, Tina; Jungbauer, Lisa et al. (2013) Levels of soluble apolipoprotein E/amyloid-? (A?) complex are reduced and oligomeric A? increased with APOE4 and Alzheimer disease in a transgenic mouse model and human samples. J Biol Chem 288:5914-26
Arold, Stephen; Sullivan, Patrick; Bilousova, Tina et al. (2012) Apolipoprotein E level and cholesterol are associated with reduced synaptic amyloid beta in Alzheimer's disease and apoE TR mouse cortex. Acta Neuropathol 123:39-52
Sokolow, Sophie; Luu, Sanh H; Nandy, Karabi et al. (2012) Preferential accumulation of amyloid-beta in presynaptic glutamatergic terminals (VGluT1 and VGluT2) in Alzheimer's disease cortex. Neurobiol Dis 45:381-7
Sokolow, Sophie; Henkins, Kristen M; Bilousova, Tina et al. (2012) AD synapses contain abundant A? monomer and multiple soluble oligomers, including a 56-kDa assembly. Neurobiol Aging 33:1545-55
Roychaudhuri, Robin; Yang, Mingfeng; Condron, Margaret M et al. (2012) Structural dynamics of the amyloid ýý-protein monomer folding nucleus. Biochemistry 51:3957-9
Sokolow, Sophie; Henkins, Kristen M; Williams, Iris A et al. (2012) Isolation of synaptic terminals from Alzheimer's disease cortex. Cytometry A 81:248-54

Showing the most recent 10 out of 12 publications